VIE - Viela Bio, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Viela Bio, Inc.

One MedImmune Way
Fifth Floor Area Two
Gaithersburg, MD 20878
United States

Full Time Employees95

Key Executives

NameTitlePayExercisedYear Born
Dr. Zhengbin YaoChairman, Pres & CEON/AN/A1966
Mr. Mitchell ChanChief Financial OfficerN/AN/A1981
Dr. Aaron Ren M.B.A., Ph.D.VP and Head of Bus. Devel. & OperationsN/AN/A1977
Ms. Kate SurdezVP & Head of HRN/AN/AN/A
Dr. Jörn Drappa M.D., Ph.D.Chief Medical Officer and Head of R&DN/AN/A1964
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Viela Bio, Inc., a clinical-stage biotechnology company, engages in the research and development of treatments for severe inflammation and autoimmune diseases in the United States. The company is developing inebilizumab, a humanized monoclonal antibody for neuromyelitis optica spectrum disorder; kidney transplant desensitization; myasthenia gravis; and IgG4-related diseases. It is also developing VIB4920 for kidney transplantation rejection and sjögren's syndrome; and VIB7734 for cutaneous lupus erythematosus. The company has a strategic collaboration with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases in Japan and Other Asia Regions. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.

Corporate Governance

Viela Bio, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.